Biological Background

The Glucagon-Like Peptide-1 Receptor (GLP-1R) is a class B GPCR expressed in pancreatic β-cells, brain, and gastrointestinal tissues, crucial for glucose homeostasis and incretin pathway regulation. Tirzepatide, an imbalanced dual GIP/GLP-1 receptor agonist, demonstrates therapeutic potential in diabetes, obesity, and metabolic dysfunction research. This breakthrough incretin-based therapy serves as a reference for GLP-1R bioassay validation.

This bioassay kit supports pharmaceutical companies developing GLP-1 receptor agonist therapies and dual-incretin therapeutics for diabetes, obesity, and metabolic disorders. Applications include drug characterization, lot release testing, stability studies, and neutralizing antibody screening.

Eurofins DiscoverX's cAMP hunter Tirzepatide (GLP-1 RA) qualified kit features CHO-K1 GLP-1R cells, EFC-based cAMP detection, and validated parameters ensuring reliable potency and NAb detection.

Product Highlights
  • Optimized and qualified with tirzepatide ensuring reliable potency measurement and neutralizing antibody detection for dual-incretin therapies
  • Ready-to-use cryopreserved CHO-K1 GLP-1R cells with EFC-based cAMP detection technology for sensitive, reproducible results
  • Complete kit includes cells, detection reagents, plating reagent, dilution buffer, control agonist (exendin-4), and 96-well plates
  • Qualified bioassay with comprehensive validation: 95.2% average recovery, 4.5% repeatability RSD, and R2 = 0.95 dilutional linearity
  • Proven inter-analyst reproducibility (RSD 11.8%) and day-to-day consistency supporting regulatory submissions and commercial QC

cAMP Hunter Tirzepatide GLP-1 RA Assay Principle

In the cAMP Hunter™ Tirzepatide (GLP-1 RA) Bioassay Kit, CHO-K1 cells overexpressing human GLP-1R utilize the receptor's natural Gαs coupling to monitor tirzepatide-mediated activation. Upon receptor stimulation, adenylyl cyclase catalyzes ATP conversion to 3′-5′ cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP is quantified using a homogeneous, gain-of-signal competitive immunoassay based on Enzyme Fragment Complementation (EFC) technology. Signal intensity correlates directly with cellular cAMP levels, higher GLP-1R activation by tirzepatide produces greater cAMP concentrations and larger assay signals.

cAMP Hunter Tirzepatide (GLP-1 RA) assay principle

cAMP Hunter Tirzepatide GLP-1 RA Qualification Data

The qualification of the cAMP Hunter™ Tirzepatide (GLP-1 RA) Bioassay Kit demonstrates robust performance and reliability for drug development and QC applications. Comprehensive validation studies confirmed excellent accuracy (mean recovery 95.2%), high repeatability (RSD 4.5%), and strong intermediate precision (RSD 11.8%) with outstanding dilutional linearity (R2 = 0.95) across the 50–150% nominal relative potency range.

The assay showed consistent performance across multiple analysts, days, and cell lots, validating its reproducibility and suitability for regulatory submissions.

Download the full qualification report to review detailed performance data and see how this kit can enhance your tirzepatide development or QC workflow.

View qualification data